Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 14/20 | 0.45 |
| ▸ | AXL | P30530 | 2/20 | 0.44 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.44 |
| ▸ | MERTK | Q12866 | 2/20 | 0.44 |
| ▸ | LOX | P28300 | 4/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27315685 | 0.91 | AXL (0.38) | LOXL2AXLTYRO3MERTKLOX | |
| SCHEMBL21128589 | 0.89 | LOXL2 (0.43) | LOXL2AXLTYRO3MERTKLOX | |
| SCHEMBL8543452 | 0.86 | LOXL2 (0.44) | LOXL2AXLTYRO3MERTKLOX | |
| SCHEMBL8579703 | 0.86 | LOXL2 (0.44) | LOXL2AXLTYRO3MERTKLOX | |
| SCHEMBL22449698 | 0.85 | LOXL2 (0.48) | LOXL2AXLTYRO3MERTKLOX | |
| SCHEMBL8530609 | 0.83 | LOXL2 (0.42) | LOXL2LOXSYK | |
| SCHEMBL15390231 | 0.83 | LOXL2 (0.44) | LOXL2LOXSYKTIPARPPIM1 | |
| SCHEMBL30771875 | 0.81 | LOXL2 (0.43) | LOXL2MERTKLOXSYKTIPARP | |
| SCHEMBL15390719 | 0.81 | LOXL2 (0.43) | LOXL2MERTKLOXSYKTIPARP | |
| SCHEMBL9893726 | 0.81 | PIM1 (0.33) | LOXL2AXLTYRO3MERTKTIPARP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230027606-A1 | BIOMARKERS FOR GRAFT-VERSUS-HOST DISEASE | INCYTE CORPORATION | 2023-01-26 | — | — | US | disclosed |
| US-11406640-B2 | JAK1 pathway inhibitors for the treatment of chronic lung allograft dysfunction | INCYTE CORPORATION (US) | 2022-08-09 | — | — | US | disclosed |
| WO-2022150676-A1 | COMBINATION THERAPY COMPRISING JAK PATHWAY INHIBITOR AND ROCK INHIBITOR | INCYTE CORPORATION (US) | 2022-07-14 | — | — | WO | disclosed |
| US-11372003-B2 | Biomarkers for graft-versus-host disease | INCYTE CORPORATION (US) | 2022-06-28 | — | — | US | disclosed |
| WO-2022125670-A1 | JAK1 PATHWAY INHIBITORS FOR THE TREATMENT OF VITILIGO | INCYTE CORPORATION (US) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022120131-A1 | JAK INHIBITOR WITH A VITAMIN D ANALOG FOR TREATMENT OF SKIN DISEASES | INCYTE CORPORATION (US) | 2022-06-09 | — | — | WO | disclosed |
| US-20220175731-A1 | JAK1 PATHWAY INHIBITORS FOR THE TREATMENT OF VITILIGO | INCYTE CORPORATION | 2022-06-09 | — | — | US | disclosed |
| WO-2021076124-A1 | USE OF JAK1 INHIBITORS FOR THE TREATMENT OF CUTANEOUS LUPUS ERYTHEMATOSUS AND LICHEN PLANUS (LP) | INCYTE CORPORATION (US) | 2021-04-22 | — | — | WO | disclosed |
| WO-2021072098-A1 | BIOMARKERS FOR GRAFT-VERSUS-HOST DISEASE | INCYTE CORPORATION (US) | 2021-04-15 | — | — | WO | disclosed |
| WO-2021072116-A1 | BIOMARKERS FOR GRAFT-VERSUS-HOST DISEASE | INCYTE CORPORATION (US) | 2021-04-15 | — | — | WO | disclosed |
| WO-2016183063-A1 | CRYSTALLINE FORMS OF A PI3K INHIBITOR | INCYTE CORPORATION (US) | 2016-11-17 | — | — | WO | disclosed |
| WO-2016183060-A1 | PROCESS FOR THE SYNTHESIS OF A PHOSPHOINOSITIDE 3-KINASE INHIBITOR | INCYTE CORPORATION (US) | 2016-11-17 | — | — | WO | disclosed |
| WO-2016183062-A1 | SALTS OF (S)-7-(1-(9H-PURIN-6-YLAMINO)ETHYL)-6-(3-FLUOROPHENYL)-3-METHYL-5H-THIAZOLO[3,2-A]PYRIMIDIN-5-ONE | INCYTE CORPORATION (US) | 2016-11-17 | — | — | WO | disclosed |
| WO-2016138363-A1 | SALTS OF PI3K INHIBITOR AND PROCESSES FOR THEIR PREPARATION | INCYTE CORPORATION (US) | 2016-09-01 | — | — | WO | disclosed |
| WO-2015191677-A1 | BICYCLIC HETEROARYLAMINOALKYL PHENYL DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2015-12-17 | — | — | WO | disclosed |
| WO-2015184305-A1 | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 | INCYTE CORPORATION (US) | 2015-12-03 | — | — | WO | disclosed |
| WO-2015157257-A1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITOR | INCYTE CORPORATION (US) | 2015-10-15 | — | — | WO | disclosed |
| WO-2015131031-A1 | JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES | INCYTE CORPORATION (US) | 2015-09-03 | — | — | WO | disclosed |
| WO-2015026818-A1 | SURVIVAL BENEFIT IN PATIENTS WITH SOLID TUMORS WITH ELEVATED C-REACTIVE PROTEIN LEVELS | INCYTE CORPORATION (US) | 2015-02-26 | — | — | WO | disclosed |
| WO-2012068450-A1 | CYCLOBUTYL SUBSTITUTED PYRROLOPYRIDINE AND PYRROLOPYRIMIDINE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2012-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11372003-B2 | Biomarkers for graft-versus-host disease | CD74, HLA-DRB1, TSG101 | LOXL2 665/4885AXL 3610/4885TYRO3 671/4885 |
| US-11406640-B2 | JAK1 pathway inhibitors for the treatment of chronic lung allograft dysfunction | JAK1, JAK3, STAT1 | LOXL2 954/4885AXL 1375/4885TYRO3 212/4885 |
| US-20220175731-A1 | JAK1 PATHWAY INHIBITORS FOR THE TREATMENT OF VITILIGO | JAK1, JAK3, JAK2 | LOXL2 239/4885AXL 924/4885TYRO3 114/4885 |
| US-20230027606-A1 | BIOMARKERS FOR GRAFT-VERSUS-HOST DISEASE | CD74, HLA-DRB1, TSG101 | LOXL2 665/4885AXL 3610/4885TYRO3 671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.